Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in HLA-A*02:01-positive patients, marking the first combination of two T cell engagers in a solid tumor. The data presentation includes a poster session on November 6 and an oral session on November 7, highlighting potential advances in immunotherapy for this rare cancer. Immunocore's ImmTAC technology aims to redirect immune cells to target cancer cells, offering new hope for difficult-to-treat tumors.
Immunocore's upcoming data presentation offers context for readers following health stocks. Of 150 US health-sector stocks on Pluang, 91 rose and 53 fell today. Notable moves include NUWE at USD 7.07 with a 27.04% gain, IOVA at USD 10.99 down 25.79%, and MESO at USD 15.83 up 18.22%. This snapshot is as of Oct 29, 2026 19:12 WIB.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
Dimensional Fund Advisors Ltd. disclosed holding a 5.07% stake in Vesuvius PLC ordinary shares as of October 28, 2026. The disclosure follows regulatory requirements under the Takeover Code, indicating significant interest in the company. Dimensional...
